Overview
WEIGAO GROUP (1066)
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People’...
- Open
- 3.260
- High
- 3.300
- Low
- 3.195
- Prev. Close
- 3.230
- Volume
- 6.70M
- Turnover
- 21.90M
- Avg Price
- 3.267
- Bid/Ask Ratio
- -0.37%
- Amplitude
- 3.25%
- 52wk High
- 5.652
- Volume Ratio
- 0.27
- Turnover Ratio
- 0.15%
- 52wk Low
- 2.820
- HK Mkt Cap
- 14.60B
- Market CapHKD
- 14.76B
- P/ETTM
- 9.30
- P/EDynamic
- 8.28
- P/EStatic
- --
- EPSTTM
- 0.353
- EPSDynamic
- 0.396
- EPSStatic
- --
- BVPS
- 6.24
- P/B
- 0.53
- HK Shares
- 4.45B
- Dividend YieldTTM
- 5.14%
- DividendTTM
- 0.169
- Shares
- 4.50B
- Min lot size
- 400
- Currency
- HKD
WEIGAO GROUP Analyst Rating
View moreForecast & Rating
Oct 26, 2026- Strong buy66.67%
- Buy11.11%
- Hold22.22%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 6
- Buy
- 1
- Hold
- 2
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Stock price rose moderately by 1.54% to HK$3.28 today, reaching an intraday high of HK$3.30, primarily driven by frequent share buyback announcements. Weigao has disclosed multiple buyback programs at HKEX recently, with management demonstrating confidence in the company's intrinsic value through concrete actions. From earnings, the past two quarters showed sustained revenue growth momentum, with Q2 reaching HK$3,955 million, up 8.66% year-over-year; however, net profit faced pressure, declining 19.07% to HK$447 million in Q2, partly reflecting elevated cost pressures. On valuation, the current P/E of 9.3x and P/B of 0.53x are notably low. Despite a year-to-date decline of 35.05%, the stock has rebounded over 12% from its 52-week low of HK$2.92, indicating some recovery. Market sentiment remains constructive, with most brokers maintaining buy ratings and consensus targets above current levels. However, net margin remains flat around 11.3%, and the turnover rate at just 0.15% indicates limited market participation, warranting close monitoring of earnings sustainability going forward.
- Nov, 13
Shandong Weigao closed down 1.67% at HKD 3.23 today against previous close of HKD 3.285, after morning strength peaking at HKD 3.27 faced afternoon profit-taking. Year-to-date, the stock has fallen 36.04%, currently trading 44.5% below its 52-week high of HKD 5.82 and 10.62% above its 52-week low of HKD 2.92. Latest Q2 results show revenue of HKD 3.955 billion up 8.66% year-on-year, yet net profit of HKD 447 million fell 19.07% YoY with margin steady at 11.3%. The divergence between revenue growth and profit decline signals margin compression. The company trades at attractive valuations: PE of 9.16x and PB of 0.52x, yields a 5.22% dividend, and has undertaken frequent share buybacks, reflecting management confidence despite earnings headwinds.
- Nov, 12
Shandong Weigao edged down 0.76% to HKD 3.285 today, reflecting a tug-of-war between near-term profit headwinds and attractive valuations. The morning session bottomed at HKD 3.26 before recovering to HKD 3.305, while the afternoon pushed to a session high of HKD 3.32 but failed to sustain, closing near lows. Q2 revenues of HKD 3.96B showed solid 8.66% YoY growth, yet net profit declined 19.07% YoY to HKD 447M and EPS dropped 18.55%, signaling margin pressure. Valuation remains compelling with a PE of 9.32 and PB of just 0.53, backed by a 5.13% dividend yield; recent frequent share buybacks signal management commitment to shareholder value. However, despite positive moves in the blood purification segment, profit deceleration remains the headwind. With the stock down 34.95% year-to-date and off 43.56% from its 52-week high of HKD 5.82, the market awaits clearer signs of earnings recovery.
- Nov, 11
Shandong Weigao declined 1.19% to HKD 3.31 today, with the morning session surging to HKD 3.345 at 09:47 before pulling back; afternoon weakness extended to HKD 3.295 at 15:55, closing at 3.310, primarily due to earnings headwinds from revenue growth failing to translate into profit expansion. Q2 operating revenue climbed 8.66% year-over-year to HKD 3.955 billion, yet net profit contracted 19.07% to HKD 447 million, signaling margin pressure. The stock has fallen 34.46% year-to-date from HKD 5.05 to 3.31, now 43% below its 52-week high of HKD 5.82, trading near extended lows. That said, management's recent stream of share buyback announcements demonstrates conviction, and the company is advancing blood purification product strategy with a prefilled syringe system deal closed; analyst consensus targets remain above spot price, while the compressed valuation (PE 9.39, PB 0.53) reflects market ambivalence on near-term profit recovery prospects.
- Nov, 9
Weigao Group edged down 1.32% to HK$3.360 today, as profit-taking pressured the stock following recent buyback announcements. Morning trading opened strong at HK$3.460 but steadily weakened through the afternoon, finally dipping to HK$3.340, with an intraday range of about 3.8%. Q2 revenue of HK$3.955 billion grew 8.66% year-over-year, yet EPS fell 18.55% to HK$0.0982 and net profit dropped 19.07%, signaling margin compression. From a valuation perspective, the stock appears significantly discounted at P/E of just 9.53 and P/B of 0.54, down 42.27% from its 52-week high of HK$5.82 and off 33.47% year-to-date. While margin pressure remains a near-term headwind, management's persistent buybacks and analyst consensus targeting above current levels suggest underlying valuation support.
News
PUBT · Shandong Weigao Reports Share Buyback in HKEX Filing
PUBT · Shandong Weigao Discloses Share Buyback in HKEX Filing
PUBT · Shandong Weigao Files HKEX Next-Day Return Disclosing Share Buyback
PUBT · Shandong Weigao Files Next-Day Return to HKEX Disclosing Share Buyback
PUBT · Shandong Weigao Files HKEX Next-Day Disclosure Return Announcing Share Buyback
Weekly Review · Weekly Recap | WEIGAO GROUP this week, consensus target above spot
